During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on ...
An innovative new treatment option for bladder cancer, recently approved by the U.S. Food and Drug Administration, has been performed for the first time in Maryland.
Patients with resected stage IIIB-C or stage IV melanoma had better long-term outcomes with nivolumab vs ipilimumab.
On Sept. 5, 2025, the U.S. Food and Drug Administration (FDA) approved Inlexzo (gemcitabine intravesical system) for adults ...
Regorafenib plus nivolumab did not improve survival over chemotherapy in patients with previously treated gastric/GEJ cancer.
The phase 3 ALBAN trial tested atezolizumab plus BCG in BCG-naïve patients with high-risk, non-muscle-invasive bladder cancer (NMIBC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback